Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Recruiting 3Completed 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 4

Conditions

Carcinoma, Non-Small-Cell Lung 51Prostatic Neoplasms 23Lung Neoplasms 17Breast Neoplasms 15Squamous Cell Carcinoma of Head and Neck 13Stomach Neoplasms 10Parkinson Disease 4, Autosomal Dominant Lewy Body 8Neoplasms 8Urinary Bladder Neoplasms 6Carcinoma, Transitional Cell 6Triple Negative Breast Neoplasms 5Non-Muscle Invasive Bladder Neoplasms 5Neoplasm Metastasis 5Head and Neck Neoplasms 5Carcinoma, Squamous Cell 5Prostatic Neoplasms, Castration-Resistant 4Ovarian Neoplasms 4Oropharyngeal Neoplasms 4Endometrial Neoplasms 4Small Cell Lung Carcinoma 3Salivary Gland Neoplasms 3Nasopharyngeal Carcinoma 3Laryngeal Neoplasms 3HER2-positive Breast Cancer 3Fallopian Tube Neoplasms 3Anatomic Stage I Breast Cancer AJCC v8 3Adenocarcinoma 3Solid Tumors 2Sarcoma 2Osteosarcoma 2

Interventions

Prednisone 5Docetaxel 4niraparib 2enzalutamide 2darolutamide 2Pluvicto 2Abiraterone Acetate 2olaparib 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1abiraterone 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Dexamethasone 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Docetaxel × 90 days × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡